Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. - Wikidata - awgldk - TriplyDB

Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis.

Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis.

http://www.wikidata.org/entity/Q37853356

about

Oral budesonide for induction of remission in ulcerative colitis Budesonide for induction of remission in Crohn's disease Anti-MAdCAM antibody for induction of remission in ulcerative colitis Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease Microparticles as controlled drug delivery carrier for the treatment of ulcerative colitis: A brief review Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2 Classical and recent advances in the treatment of inflammatory bowel diseases Use of the tumor necrosis factor-blockers for Crohn's disease IBS-like symptoms in patients with ulcerative colitis Electrochemiluminescence immunoassay method underestimates cortisol suppression in ulcerative colitis patients treated with oral prednisone Vedolizumab for Crohn's disease.Inflammatory bowel disease therapies discontinued between 2009 and 2014.Managing refractory Crohn's disease: challenges and solutions Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease.A phase II study of laquinimod in Crohn's disease.Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.In vitro sensitivity assays and clinical response to glucocorticoids in patients with inflammatory bowel disease.Enhanced production of early lineages of monocytic and granulocytic cells in mice with colitis Steroids and 5-aminosalicylic acids in moderate ulcerative colitis: addressing the dilemma.High-resolution Quantitative Computed Tomography Demonstrates Structural Defects in Cortical and Trabecular Bone in IBD Patients.Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study.Second Korean guidelines for the management of Crohn's disease.Second Korean guidelines for the management of ulcerative colitis.An evidence-based systematic review on medical therapies for inflammatory bowel disease.Second-generation corticosteroids for the treatment of Crohn's disease and ulcerative colitis: more effective and less side effects?Comparing medical treatments for Crohn's disease.New biologic therapeutics for ulcerative colitis and Crohn's disease.Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis.Role in calcineurin inhibitors for inflammatory bowel disease in the biologics era: when and how to use.Drug therapies for ulcerative proctitis: systematic review and meta-analysis.Conventional drug therapy for inflammatory bowel disease.Inflammatory bowel disease meta-evidence and its challenges: is it time to restructure surgical research?Drug Management in the Elderly IBD Patient.Indian Society of Gastroenterology consensus statements on Crohn's disease in India.Asia-Pacific consensus statements on Crohn's disease. Part 2: Management.Safety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse events.Systematic review: thalidomide and thalidomide analogues for treatment of inflammatory bowel disease.CCR9 antagonism: potential in the treatment of Inflammatory Bowel Disease.Treating children with inflammatory bowel disease: Current and new perspectives.Vedolizumab for the treatment of ulcerative colitis.

P2860

Q24186368-DBFC8E0C-452D-4F18-86EB-6F52EC2FE559 Q24187309-BAF262DC-016B-42F0-91E2-FC4AD92D6F82 Q24187593-0E260A99-393E-4B68-8504-346A23ED03B0 Q24188040-B7EACCAB-9D6E-440F-B1F8-08528B66C44A Q26743907-EAA6CE3F-370A-4A13-8CEA-FE1324572B4E Q26798299-1DFAABCF-64A0-47F8-B6BA-207E57DBE6D2 Q26861725-3E48F1E6-487F-46FD-BE09-4E5170368C6E Q27030762-455DBC77-BDEB-4F25-908F-ADAD4A5FA2E8 Q28088663-2B504FA0-EF6B-4594-B233-F090F046F4EC Q34067898-62FB8A74-6E0B-4373-A9DD-EFFDD8BFC7DB Q34326912-3A93F30F-03F4-4D35-A595-9AD9D5C10314 Q34471161-00E6F695-F7F5-4021-9017-43EBBAD1AECB Q35460367-B7BDF85C-688F-4298-8CBE-17730DAB3842 Q35599763-050D920E-BE68-4B6D-BCA8-3AE3E262A92A Q35891861-1322ADA1-9966-42CD-B7AC-4CBF33E8A76B Q36203845-CC3B156B-CE8E-448E-89BB-9EB33A549233 Q36288157-BFC2966F-5014-4F12-9590-CD9C2A651CC5 Q36339826-6581B59D-0F77-43DB-8465-8CF1B7131A51 Q36515613-AC4A028A-63E1-44B1-81FB-27679464C85C Q37118418-969EC523-999A-46FF-9437-3832E0D2CFCA Q37600339-1B2613BE-BC3E-495D-AE38-46438F266C73 Q37662498-F6C659F2-02C8-4E7C-9EC3-3B41E8CF1C20 Q37662503-94177F43-A43B-451D-AD2B-9E56FB1FC98F Q37862584-A058F500-DD5D-4AFB-AF68-C047AB7E2446 Q38026396-CE1FF925-CAB2-4B45-A57D-CE553B35282F Q38162880-7226D4A0-344F-4FD0-855A-11CEFEB4607D Q38185687-7DF0AD83-D590-4732-A825-13BF98FDD6A7 Q38196945-2BF48D31-24E1-4D47-9159-770AE791C3BB Q38230163-64DCB194-C8CF-4CAE-BEE0-68BB97E5D797 Q38235056-9CFB3F19-0D30-4C0C-8D5E-AC6D6F432E7B Q38293796-BE784148-C21C-45D7-A4E0-7AB1DD028083 Q38302725-70006F87-CB6F-4ACA-8F12-B29129BBBAEC Q38330651-1ECBAAAF-2E2A-4CD5-8DEB-16EE5C263627 Q38378837-5AE68A99-7782-4E51-9825-F3EAFE84906F Q38394726-9B31DBAB-8615-4590-B2C6-EA95B0C9D6BC Q38394816-3DDC9F1C-5687-4C4D-B953-564D83ADCD1A Q38413494-02DC98D1-A384-4827-BA8B-A469B9C39F36 Q38432470-B4BD82B4-747F-498C-A95D-631F3A9F8507 Q38602911-E08CCA0A-D391-4D5C-8A85-952A38CC73EB Q38633318-BF99D6F1-D363-48FD-911F-9BEEFB011AE4

P2860

Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis.

http://www.wikidata.org/entity/Q37853356

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 15 March 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Glucocorticosteroid therapy in ...... atic review and meta-analysis.

@en

Glucocorticosteroid therapy in ...... atic review and meta-analysis.

@en-gb

Glucocorticosteroid therapy in ...... atic review and meta-analysis.

@nl

type

label

Glucocorticosteroid therapy in ...... atic review and meta-analysis.

@en

Glucocorticosteroid therapy in ...... atic review and meta-analysis.

@en-gb

Glucocorticosteroid therapy in ...... atic review and meta-analysis.

@nl

prefLabel

Glucocorticosteroid therapy in ...... atic review and meta-analysis.

@en

Glucocorticosteroid therapy in ...... atic review and meta-analysis.

@en-gb

Glucocorticosteroid therapy in ...... atic review and meta-analysis.

@nl

P1433

Q37853356-E92F14F2-6CDA-4689-9089-0B702152EF3E

P1476

Q37853356-5F462049-7D64-458A-BAF6-41057A91DCF6

P2093

Q37853356-67B93E52-3C9D-4BA5-AE28-CFC31016CCD9

Q37853356-785BCE88-65A0-4768-81E8-CA1DB4BFABA7

Q37853356-CAD182EC-F387-44E3-97B8-3CFEDD82D756

Q37853356-F67C35C0-9855-458D-A885-A4C6D6CA09A3

Q37853356-FD69757D-8BB5-4C42-88A4-61BF1CAFE843

P2860

Q37853356-04B6596F-DD61-4DA0-8814-51B1803C69D5

Q37853356-0745D4D8-2FB4-4544-A189-E1AF6C1E6D4B

Q37853356-1A61D045-8D94-4FCB-AF6C-1A3F5407C923

Q37853356-1E78EDC9-8E96-443D-8DCA-B2E419CA316B

Q37853356-26D1F316-2BB1-4309-821C-A3E66A97B8D4

Q37853356-2937EB2E-B42E-439F-99C9-8B5AAB38E8F2

Q37853356-2C2A3ED1-9FB6-4599-95BD-35BD404CE219

Q37853356-34793202-C2DD-41DC-A698-60E07624230C

Q37853356-42519C05-3DC3-4000-8827-FA04A99A17E9

Q37853356-4B8820D3-EEDF-40FF-8D01-279BA333B957

P304

Q37853356-C55A033D-52A5-4A13-91CF-262449FF9117

P31

Q37853356-351DA9E5-8B25-46D5-8289-6E5B643F3877

Q37853356-ed147e9d-d2c0-415e-b9cd-a7cc94ae9997

P356

Q37853356-47B08096-7345-4EF0-A137-2BB086347241

P407

Q37853356-71BADB39-724E-4137-9AD1-41E8DE10AD6C

P433

Q37853356-AF07C4D9-5655-4232-AD7C-67BA48D7587F

P478

Q37853356-6EA27701-1E85-4D44-A4DC-61E3425192D0

P50

Q37853356-0E4E79A1-4379-4042-8B32-7AD0FEA530D8

Q37853356-8BB08EEB-A41B-4395-96A6-BFDAA0DECF7B

P577

Q37853356-088A06B0-6178-4C6B-9EC9-6C7404FDA382

P5875

Q37853356-07DBD0F7-9B6C-4A92-8265-04BCE3C67BFF

P698

Q37853356-9C21ACC0-BF8B-4BE2-AD1A-D6B55499F4BD

P921

Q37853356-95B48508-B600-4414-A185-3778FEA925A3

Q37853356-9BA8CA1E-6F69-4767-8F4D-191B99479CD8

Q37853356-C2A776A8-EBB7-404F-B627-39089E62792E

P356

P1433

The American Journal of Gastroenterology

P1476

Glucocorticosteroid therapy in ...... atic review and meta-analysis.

@en

P2093

Charles N Bernstein

http://www.w3.org/2001/XMLSchema#string

John K Marshall

http://www.w3.org/2001/XMLSchema#string

Khurram J Khan

http://www.w3.org/2001/XMLSchema#string

Maria T Abreu

http://www.w3.org/2001/XMLSchema#string

Nicholas J Talley

http://www.w3.org/2001/XMLSchema#string

P2860

Bias in meta-analysis detected by a simple, graphical test

Measuring inconsistency in meta-analyses

Meta-analysis in clinical trials

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group

Effects of glucocorticoids on gene transcription

Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease

Systematic reviews in health care: Assessing the quality of controlled clinical trials

[Budesonide in inflammatory bowel disease: a meta-analysis]

Oral fluticasone propionate in active distal ulcerative colitis.

Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study.

P304

590-9; quiz 600

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/AJG.2011.70

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P50

Alexander C. Ford

P577

2011-03-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50399176

http://www.w3.org/2001/XMLSchema#string

P698

21407179

http://www.w3.org/2001/XMLSchema#string

P921

inflammatory bowel diseases